Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹3,478Cr
Rev Gr TTM
Revenue Growth TTM
16.63%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

BHAGCHEM
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -11.0 | -17.8 | -7.4 | -41.0 | -9.2 | 11.4 | -15.0 | 38.1 | 10.2 | 11.1 | 35.1 | 10.9 |
| 104 | 93 | 109 | 66 | 97 | 99 | 94 | 94 | 117 | 115 | 125 | 100 |
Operating Profit Operating ProfitCr |
| 14.9 | 7.1 | 11.0 | 11.1 | 12.7 | 10.8 | 9.4 | 8.9 | 5.0 | 7.3 | 10.8 | 12.0 |
Other Income Other IncomeCr | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 2 | 1 | 1 | 0 | 1 |
Interest Expense Interest ExpenseCr | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 3 | 4 | 3 |
Depreciation DepreciationCr | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 |
| 14 | 3 | 9 | 5 | 11 | 10 | 8 | 6 | 2 | 3 | 8 | 6 |
| 5 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 3 | -1 | 2 | 2 |
|
Growth YoY PAT Growth YoY% | -13.7 | -83.5 | -53.1 | -71.5 | -23.1 | 189.8 | -4.9 | 8.1 | -112.2 | -30.3 | 1.1 | 28.7 |
| 7.7 | 2.0 | 4.7 | 4.5 | 6.5 | 5.1 | 5.2 | 3.5 | -0.7 | 3.2 | 3.9 | 4.0 |
| 0.9 | 0.2 | 0.6 | 0.3 | 0.1 | 0.5 | 0.4 | 0.3 | -0.1 | 0.3 | 0.4 | 0.4 |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 29.4 | 37.0 | 15.3 | -18.8 | 8.1 | 13.6 |
| 229 | 271 | 367 | 425 | 365 | 404 | 457 |
Operating Profit Operating ProfitCr |
| 6.9 | 14.8 | 15.7 | 15.4 | 10.5 | 8.4 | 8.8 |
Other Income Other IncomeCr | 4 | 2 | 1 | 1 | 3 | 9 | 3 |
Interest Expense Interest ExpenseCr | 5 | 8 | 9 | 5 | 8 | 7 | 12 |
Depreciation DepreciationCr | 7 | 8 | 9 | 10 | 11 | 14 | 16 |
| 9 | 32 | 51 | 64 | 27 | 25 | 19 |
| 2 | 9 | 16 | 19 | 9 | 11 | 5 |
|
| | 258.4 | 53.3 | 26.3 | -59.6 | -23.9 | -4.6 |
| 2.6 | 7.3 | 8.2 | 9.0 | 4.5 | 3.1 | 2.6 |
| 0.7 | 2.5 | 3.8 | 4.4 | 0.2 | 1.1 | 1.0 |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 8 | 8 | 8 | 10 | 10 | 13 | 13 |
| 124 | 147 | 182 | 303 | 318 | 669 | 677 |
Current Liabilities Current LiabilitiesCr | 83 | 95 | 133 | 101 | 126 | 195 | 207 |
Non Current Liabilities Non Current LiabilitiesCr | 10 | 22 | 19 | 33 | 37 | 56 | 143 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 79 | 114 | 174 | 228 | 280 | 375 | 392 |
Non Current Assets Non Current AssetsCr | 147 | 159 | 168 | 219 | 296 | 558 | 648 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 48 | 4 | 7 | 14 | 34 | -53 |
Investing Cash Flow Investing Cash FlowCr | -39 | -21 | -17 | -60 | -116 | -200 |
Financing Cash Flow Financing Cash FlowCr | -9 | 15 | 12 | 46 | 88 | 272 |
|
Free Cash Flow Free Cash FlowCr | 9 | -17 | -10 | -46 | -45 | -302 |
| 740.1 | 15.3 | 18.5 | 30.8 | 188.2 | -381.0 |
CFO To EBITDA CFO To EBITDA% | 284.5 | 7.6 | 9.7 | 18.0 | 79.9 | -142.9 |
| Financial Year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 209 | 420 | 844 | 1,245 | 1,676 | 3,605 |
Price To Earnings Price To Earnings | 32.1 | 18.1 | 23.7 | 27.6 | 92.0 | 259.8 |
Price To Sales Price To Sales | 0.8 | 1.3 | 1.9 | 2.5 | 4.1 | 8.2 |
Price To Book Price To Book | 1.6 | 2.7 | 4.5 | 4.0 | 5.1 | 5.3 |
| 14.4 | 10.3 | 13.5 | 16.7 | 40.2 | 99.2 |
Profitability Ratios Profitability Ratios |
| 35.0 | 36.8 | 36.5 | 37.6 | 39.5 | 36.9 |
| 6.9 | 14.8 | 15.7 | 15.4 | 10.5 | 8.4 |
| 2.6 | 7.3 | 8.2 | 9.0 | 4.5 | 3.1 |
| 8.4 | 18.5 | 22.3 | 18.9 | 8.9 | 4.2 |
| 4.9 | 15.0 | 18.8 | 14.4 | 5.5 | 2.0 |
| 2.9 | 8.5 | 10.4 | 10.1 | 3.2 | 1.5 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Bhagiradha Chemicals & Industries Limited (BCIL) is a leading Indian agrochemical manufacturer listed on the BSE (531719) and NSE (BHAGCHEM), headquartered in Hyderabad, Telangana. Founded in **1993** by the late **Sri Singavarapu Koteswara Rao**, a former scientist at the Indian Institute of Chemical Technology (IICT), Hyderabad, BCIL has evolved into an R&D-driven, vertically integrated player in the global agrochemical supply chain. The company specializes in the manufacture of **technical-grade pesticides** — including insecticides, herbicides, fungicides, and specialty intermediates — serving regulated markets across more than 25 countries.
---
### **Core Business & Strategic Focus**
BCIL operates as a science-led, innovation-focused enterprise with key competitive advantages in:
- **Deep backward integration** (up to N-7/N-9 stages)
- **In-house R&D for non-infringing synthesis processes**
- **Rapid product development and scale-up capabilities**
- **Regulatory compliance for export to high-barrier markets**
- **Cost efficiency and competitive pricing without compromising quality**
The company aims to deliver sustainable growth by capitalizing on off-patent molecules, expanding manufacturing capacity, and strengthening its presence in regulated global markets.
---
### **Operational Profile**
| **Parameter** | **Details** |
|--------------|-----------|
| **Established** | 1993 |
| **Founders** | Late S. Koteswara Rao & S. Dodda Sadasivudu |
| **Listed On** | BSE (1996), NSE |
| **Headquarters** | Hyderabad, Telangana |
| **Managing Director** | Mr. S. Chandrasekhar (former R&D head) |
| **Global Presence** | Exports to >25 countries |
| **Employee Strength** | ~700 (direct and indirect) |
#### **Manufacturing Facilities**
1. **Ongole, Andhra Pradesh**
- Installed capacity: **3,250 MTPA**
- 3 production blocks, 4–5 process lines
- Utilization: ~80%
- Products: 7–10 AI/intermediates/formulations annually
- Features: Zero Liquid Discharge (ZLD) ETP, modernized utilities, on-site R&D & pilot plant
- Key products: Chlorpyriphos, Imidacloprid, Azoxystrobin, Fipronil, Thiamethoxam
2. **Karnataka Facility (Under Development)**
- Subsidiary: **Bheema Fine Chemicals Private Limited**
- Planned Capacity: **9,002 MTPA**
- Status: Environmental clearance secured; Phase I operational from 2024, full production expected Q2 FY25–26
- Advantages: Modular design, on-site TSDF, assured water (KIADB), proximity to skilled labor, solar-powered operations
#### **R&D Capabilities**
- Government-approved **DSIR-recognized R&D center** located at Ongole plant.
- **Over 60 chemists**, 8 synthesis labs, pilot & semi-commercial plants.
- Strategic collaborations with **MNCs from the US, Japan, and Israel**, and research tie-up with **IICT, Hyderabad**.
- Focus areas: Non-infringing process development for off-patent molecules, cost optimization, IP generation.
- **28+ products commercialized**, all developed in-house; pipeline of 3–4 new molecules/year.
- **Two Indian patents granted**:
- High-purity trifluoromethyl sulfinyl chloride synthesis (hypervalent iodine catalyst)
- Process for [1,4,5]-oxadiazepane salts
#### **Financial Performance**
- **Revenue FY24**: ₹408 crores
- **Crossed ₹500 crores in turnover during CY2023**
- Strong volume recovery from **H2 FY25**, with **double-digit growth in H1 FY26** despite pricing pressures
- Target: **₹2,500 crores+ revenue by FY31–32**
#### **Sustainability Initiatives**
- Commissioned a **4 MW solar power plant** at Ongole facility, reducing energy costs and carbon footprint.
- Investment of **₹70–100 crore in solar projects** under capex plan.
- Zero Liquid Discharge (ZLD), advanced ETP (Reverse Osmosis, Multiple Effect Evaporators), green belt (>60% of site area).
---
### **Market Position & Competitive Edge**
- **Domestic Market Share**: ~27% in key agrochemical segments
- **Global Market Share**: ~6%
- One of the few Indian manufacturers with deep backward integration in complex molecules like **Azoxystrobin, Fipronil, and Trifloxystrobin**.
- High gross material margins due to proprietary processes and integrated supply chain.
- Positioned as a **trusted supplier in regulated markets**, supported by IPR ownership and compliance with global standards.
---
### **Recent Milestones (2024–2025)**
- Commercial launch of **Trifloxystrobin**, a top-tier fungicide effective across key crops (rice, grapes, mango, tomato).
- Introduction of **Chlorantraniliprole**, a low-toxicity, IPM-compatible diamide insecticide.
- Commencement of operations at **Bheema Fine Chemicals (March 2024)**.
- Expansion of **export market reach to Bangladesh and Africa**.
- Implementation of **ERP systems** to enhance decision-making and operational efficiency.
- Strengthened **registration department** to fast-track approvals in domestic and international markets.
---
### **Risks & Mitigation**
| **Risk** | **Response Strategy** |
|--------|----------------------|
| Raw material price volatility | Enhanced backward integration, inventory optimization |
| Chinese import competition | Cost-efficient, locally produced alternatives; "China +1" alignment |
| Regulatory delays | Strengthened registration team; parallel approval filings |
| Single-site dependence (AP plant) | Risk mitigated by Karnataka greenfield project (multi-product, flexible facility) |
| Geopolitical & trade shifts | Diversified geography and customer portfolio |